• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Infect D . Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2

tetano

Editor, Senior Moderator
ACS Infect Dis


. 2021 Mar 16.
doi: 10.1021/acsinfecdis.0c00725. Online ahead of print.
Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2


Simon Fink[SUP] 1 [/SUP], Felix Ruoff[SUP] 1 [/SUP], Aaron Stahl[SUP] 1 [/SUP], Matthias Becker[SUP] 1 [/SUP], Philipp Kaiser[SUP] 1 [/SUP], Bjoern Traenkle[SUP] 2 [/SUP], Daniel Junker[SUP] 1 [/SUP], Frank Weise[SUP] 1 [/SUP], Natalia Ruetalo[SUP] 3 [/SUP], Sebastian H?rber[SUP] 4 5 6 [/SUP], Andreas Peter[SUP] 4 5 6 [/SUP], Annika Nelde[SUP] 7 8 9 [/SUP], Juliane Walz[SUP] 7 8 9 10 [/SUP], G?rard Krause[SUP] 11 12 [/SUP], Armin Baillot[SUP] 13 [/SUP], Katja Schenke-Layland[SUP] 1 9 14 15 [/SUP], Thomas O Joos[SUP] 1 [/SUP], Ulrich Rothbauer[SUP] 1 2 [/SUP], Nicole Schneiderhan-Marra[SUP] 1 [/SUP], Michael Schindler[SUP] 3 [/SUP], Markus F Templin[SUP] 1 [/SUP]



Affiliations

Abstract

The presence of antibodies against endemic coronaviruses has been linked to disease severity after SARS-CoV-2 infection. Assays capable of concomitantly detecting antibodies against endemic coronaviridae such as OC43, 229E, NL63, and SARS-CoV-2 may help to elucidate this question. We developed a serum screening platform using a bead-based Western blot system called DigiWest, capable of running hundreds of assays using microgram amounts of protein prepared directly from different viruses. Characterization of the immunoassay for detection of SARS-CoV-2 specific antibodies revealed a sensitivity of 90.3% and a diagnostic specificity of 98.1%. Concordance analysis with the SARS-CoV-2 immunoassays available by Roche, Siemens, and Euroimmun indicates comparable assay performances (Cohen's ? ranging from 0.8874 to 0.9508). Analogous assays for OC43, 229E, and NL63 were established and combined into one multiplex with the SARS-CoV-2 assay. Seroreactivity for different coronaviruses was detected with high incidence, and the multiplex assay was adapted for serum screening.

Keywords: COVID-19; Luminex; SARS-CoV-2; Western blot; endemic coronavirus; serology.
 
Back
Top Bottom